{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:23:39Z","timestamp":1786123419744,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Sugammadex is associated with fewer postoperative pulmonary complications than is neostigmine reversal of neuromuscular blockade. However, the Food and Drug Administration-approved package insert states that its use is \u201cnot recommended\u201d in severe renal impairment, separately defined as creatinine clearance &lt;30 mL\/min. Recently, the formula for estimating glomerular filtration rate (GFR) was updated to remove the race variable. Compared to the prior formula, the new consensus equation lowers the estimated GFR for African American patients and raises it for everyone else. We sought to determine how this change could differently impact the use of sugammadex, and thus the rate of pulmonary complications, for both African American and non-African American patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>We used Monte Carlo simulation models to estimate the difference in pulmonary complications that would be suffered by patients when the change in creatine clearance calculated from the estimated GFR (using the old race-based and new race-neutral Chronic Kidney Disease Epidemiology Collaboration formulas) crossed the 30 mL\/min threshold, which would require a change in sugammadex or neostigmine use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>We found that 0.22% (95% confidence interval 0.14%\u20130.36%) of African American patients\u2019 creatinine clearance would drop from above to below 30 mL\/min making sugammadex not recommended and 0.19% (0.16%\u20130.22%) of non-African American patients would have creatinine clearance increase to &gt;30 mL\/min making sugammadex now recommended. Based on our model, we estimate that African American patients would suffer (count [95% confidence interval]) 3 [0.4\u20136] more pulmonary complications per 100,000 African American patients who received rocuronium or vecuronium through the change from sugammadex to neostigmine reversal to comply with labeling recommendations. Conversely, the same change in formulas would reduce the number of non-African American patients suffering pulmonary complications by 3 [2\u20134] per 100,000.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>The recent change in GFR formulas may potentially be associated with an increase in postoperative pulmonary complications in African American patients and a decrease in postoperative pulmonary complications in non-African American patients through GFR-driven changes in sugammadex use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1213\/ane.0000000000006896","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T13:04:23Z","timestamp":1707743063000},"page":"1038-1046","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Effect of Changing Estimated Glomerular Filtration Rate Formula on Sugammadex Use and Pulmonary Complications for African American and non-African American Patients"],"prefix":"10.1213","volume":"139","author":[{"given":"Milo","family":"Engoren","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heung","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"issue":"suppl 1","key":"R1-20250502","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2044.2008.05867.x","article-title":"Antagonism of non-depolarising neuromuscular block: current practice.","volume":"64","author":"Kopman","year":"2009","journal-title":"Anaesthesia"},{"key":"R2-20250502","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/ALN.0000000000000674","article-title":"Dose-dependent association between intermediate-acting neuromuscular-blocking agents and postoperative respiratory complications.","volume":"122","author":"McLean","year":"2015","journal-title":"Anesthesiology"},{"key":"R3-20250502","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/ALN.0000000000001409","article-title":"Current status of neuromuscular reversal and monitoring: challenges and opportunities.","volume":"126","author":"Brull","year":"2017","journal-title":"Anesthesiology"},{"key":"R4-20250502","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/ALN.0000000000003256","article-title":"Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (STRONGER): a multicenter matched cohort analysis.","volume":"132","author":"Kheterpal","year":"2020","journal-title":"Anesthesiology"},{"key":"R5-20250502","first-page":"266","article-title":"A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host.","volume":"41","author":"Bom","year":"2002","journal-title":"Angew Chem Int Ed Engl"},{"key":"R6-20250502","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/00000542-200309000-00018","article-title":"Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969.","volume":"99","author":"Epemolu","year":"2003","journal-title":"Anesthesiology"},{"key":"R7-20250502","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/00000542-200510000-00007","article-title":"First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide.","volume":"103","author":"Gijsenbergh","year":"2005","journal-title":"Anesthesiology"},{"key":"R8-20250502","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/01.anes.0000265152.78943.74","article-title":"Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics.","volume":"106","author":"Sparr","year":"2007","journal-title":"Anesthesiology"},{"key":"R9-20250502","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/EJA.0000000000000312","article-title":"Efficacy and safety of sugammadex in the reversal of deep neuromuscular blockade induced by rocuronium in patients with end-stage renal disease: a comparative prospective clinical trial.","volume":"32","author":"de Souza","year":"2015","journal-title":"Eur J Anaesthesiol"},{"key":"R10-20250502","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/bja\/aep340","article-title":"Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study.","volume":"104","author":"Staals","year":"2010","journal-title":"Br J Anaesth"},{"key":"R12-20250502","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/cts.13061","article-title":"Design and conduct considerations for studies in patients with impaired renal function.","volume":"14","author":"Ravenstijn","year":"2021","journal-title":"Clin Transl Sci"},{"key":"R13-20250502","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bja.2023.02.031","article-title":"An educational intervention to reduce the incidence of postoperative residual curarisation: a cluster randomised crossover trial in patients undergoing general anaesthesia.","volume":"131","author":"D\u00edaz-Cambronero","year":"2023","journal-title":"Br J Anaesth"},{"key":"R14-20250502","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R15-20250502","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1681\/ASN.2021070988","article-title":"A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease.","volume":"32","author":"Delgado","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R16-20250502","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/EJA.0000000000000118","article-title":"Standards for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine: European Perioperative Clinical Outcome (EPCO) definitions: a statement from the ESA-ESICM joint taskforce on perioperative outcome measures.","volume":"32","author":"Jammer","year":"2015","journal-title":"Eur J Anaesthesiol"},{"key":"R17-20250502","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/0272989X8300300403","article-title":"The Markov process in medical prognosis.","volume":"3","author":"Beck","year":"1983","journal-title":"Med Decis Making"},{"key":"R18-20250502","first-page":"119","article-title":"Approximate is better than \u201cexact\u201d for interval estimation of binomial proportions.","volume":"52","author":"Agresti","year":"1998","journal-title":"Am Stat"},{"key":"R19-20250502","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003088-199936010-00003","article-title":"Clinical pharmacokinetics of cisatracurium besilate.","volume":"36","author":"Kisor","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"R20-20250502","doi-asserted-by":"crossref","first-page":"848","DOI":"10.2165\/00003495-199753050-00012","article-title":"Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice.","volume":"53","author":"Bryson","year":"1997","journal-title":"Drugs"},{"key":"R21-20250502","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","article-title":"Metformin-associated lactic acidosis: Current perspectives on causes and risk.","volume":"65","author":"DeFronzo","year":"2016","journal-title":"Metabolism"},{"key":"R22-20250502","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1681\/ASN.2019101119","article-title":"The FDA metformin label change and racial and sex disparities in metformin prescription among patients with CKD.","volume":"31","author":"Shin","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"R23-20250502","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1001\/jama.2022.15404","article-title":"Reported awareness and adoption of 2021 estimated glomerular filtration rate equations among US clinical laboratories, March 2022.","volume":"328","author":"Genzen","year":"2022","journal-title":"JAMA"},{"key":"R24-20250502","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clinbiochem.2018.01.005","article-title":"Combined creatinine-cystatin C CKD-EPI equation significantly underestimates measured glomerular filtration rate in people with type 2 diabetes mellitus.","volume":"53","author":"Machado","year":"2018","journal-title":"Clin Biochem"},{"key":"R25-20250502","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejim.2020.04.044","article-title":"Comparison of bias and accuracy using cystatin C and creatinine in CKD-EPI equations for GFR estimation.","volume":"80","author":"Zou","year":"2020","journal-title":"Eur J Intern Med"},{"key":"R26-20250502","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/ALN.0000000000002412","article-title":"Differences of recovery from rocuronium-induced deep paralysis in response to small doses of sugammadex between elderly and nonelderly patients.","volume":"129","author":"Muramatsu","year":"2018","journal-title":"Anesthesiology"},{"key":"R27-20250502","first-page":"238","article-title":"Sugammadex for reversal of neuromuscular blockade in a patient with renal failure.","volume":"24","author":"Pfaff","year":"2019","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R28-20250502","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/bja\/aet586","article-title":"Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg-1 for reversal of deep neuromuscular blockade in patients with severe renal impairment.","volume":"114","author":"Panhuizen","year":"2015","journal-title":"Br J Anaesth"},{"key":"R29-20250502","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/bja\/aen216","article-title":"Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function.","volume":"101","author":"Staals","year":"2008","journal-title":"Br J Anaesth"},{"key":"R30-20250502","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/anae.14914","article-title":"Short-term safety and effectiveness of sugammadex for surgical patients with end-stage renal disease: a two-centre retrospective study.","volume":"75","author":"Adams","year":"2020","journal-title":"Anaesthesia"},{"key":"R31-20250502","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s12630-020-01812-3","article-title":"Sugammadex use in patients with end-stage renal disease: a historical cohort study.","volume":"67","author":"Paredes","year":"2020","journal-title":"Can J Anaesth"},{"key":"R32-20250502","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.3390\/ijerph18052411","article-title":"Racial and ethnic disparities in US veteran health characteristics.","volume":"18","author":"Ward","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"R33-20250502","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3109\/0886022X.2015.1117924","article-title":"Prevalence of various comorbidities among veterans with chronic kidney disease and its comparison with other datasets.","volume":"38","author":"Patel","year":"2016","journal-title":"Ren Fail"},{"key":"R34-20250502","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/ALN.0000000000004379","article-title":"American Society of Anesthesiologists practice guidelines for monitoring and antagonism of neuromuscular blockade: a report by the American Society of Anesthesiologists Task Force on Neuromuscular Blockade.","volume":"138","author":"Thilen","year":"2023","journal-title":"Anesthesiology"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000006896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:30:31Z","timestamp":1786113031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000006896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0000000000006896","relation":{},"ISSN":["0003-2999","1526-7598"],"issn-type":[{"value":"0003-2999","type":"print"},{"value":"1526-7598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]}}}